Abstracts tagged "IL-1"

Abstract Number: 44 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut⁴, Katherine Marzan⁵, Nico Wulffraat², Rayfel Schneider⁵, Shai Padeh⁶, Vyacheslav Chasnyk⁶, Carine Wouters⁶, Jasmin B. Kuemmerle-Deschner⁶, Tilmann Kallinich⁶, Bernard Lauwerys⁷, Elie Haddad⁵, Evgeny L Nasonov⁶, Maria Trachana⁶, Olga Vougiouka⁶, Karolynn Leon⁸, Eleni Vritzali⁹, Karine Lheritier¹⁰, Alberto Martini⁶ and Daniel Lovell⁵, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁵PRCSG, Cincinnati, OH, ⁶PRINTO-Istituto Gaslini, Genova, Italy, ⁷Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN) demonstrated…
Abstract Number: 2256 • 2016 ACR/ARHP Annual Meeting
Histopathologic Features and Tissue Interferon-Response Gene Scoring of Lesional Skin Samples for Diagnosis in Autoinflammatory Disorders
Kyawt W. Shwin^1,2, Chyi-Chia Richard Lee³, Adriana Almeida de Jesus⁴, Carmelo Carmona-Rivera⁵, Louise Malle⁴, Yanfeng Hou⁶, Gina A. Montealegre Sanchez⁴, Edward Cowen⁷ and Raphaela Goldbach-Mansky⁸, ¹Translational Autoinflammatory Diseases Studies, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Dermatopathology Section, Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁵Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ⁷Dermatology Branch, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, ⁸Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Many genetically defined autoinflammatory diseases (AID) are caused by innate immune dysregulation and present with “neutrophilic dermatoses”. This study systematically assesses immune-cell infiltrates, and…
Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Ronald Berenson¹, Maura-Ann Matthews¹, Wayne Wallis², Raj Dua¹, Margaret Moore¹, Robert Terkeltaub³ and Christopher Clegg^1,4, ¹Aequus BioPharma, Inc., Seattle, WA, ²Dyad Life Sciences, LLC, Seattle, WA, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴TRIA Bioscience, Seattle, WA
Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
Abstract Number: 2788 • 2016 ACR/ARHP Annual Meeting
Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus
Jeremy Tilstra¹, Sheldon Bastacky² and Mark Shlomchik³, ¹Rheumatology, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease defined by autoantibody production, immune dysregulation, and end-organ damage. Our laboratory previously showed that MyD88,…
Abstract Number: 3071 • 2016 ACR/ARHP Annual Meeting
Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Marwa Qadri¹, Tannin Schmidt², Khaled Elsaid³ and Gregory Jay⁴, ¹Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ²Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, ⁴Emergency Medicine, Brown University, Providence, RI
Background/Purpose: Gout is an inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in synovial joints. MSU crystals interact with resident macrophages that…
Abstract Number: 3076 • 2016 ACR/ARHP Annual Meeting
Development of a Matrix-Binding Interlukin-1 Receptor Antagonist Fusion Protein for Extended Retention in the Joint Tissues
James Pancoast¹, Richard Lee^2,3 and Parth Patwari¹, ¹ProteoThera, Inc., Newton, MA, ²Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, ³Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A primary challenge for intra-articular delivery of protein and peptide therapies has been their short residence time in the joint tissues. The IL-1 receptor…
Abstract Number: 3147 • 2016 ACR/ARHP Annual Meeting
Remote Inflammation Triggers Autoimmune Arthritis through Th17 Distribution
Nina Chevalier¹, Jian Tan², Linda Mason², Remy Robert², Craig McKenzie², Seth Masters³ and Charles Mackay², ¹University Freiburg Medical Center, Freiburg, Germany, ²Monash University, Melbourne, Australia, ³WEHI, Melbourne, Australia
Background/Purpose: Autoimmune diseases, such as autoimmune inflammatory arthritis, result through breakdown of immune tolerance and development of self-reactive T cells, or autoantibody-producing B cells. Tolerance…
Abstract Number: 214 • 2016 ACR/ARHP Annual Meeting
Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Alexandre Dumusc¹, Borbala Pazar Maldonado¹, Charles Benaim², Isabelle Fabreguet¹, Pascal Zufferey¹, Bérengère Aubry-Rozier¹ and Alexander So¹, ¹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ²Physical Medicine and Rehabilitation Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate crystal-induced arthritis (CPPD) is an acute crystal arthritis, frequently involving the wrist or the knee. Monosodium urate in gout or CPPD…
Abstract Number: 653 • 2016 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Highly Expressed By Salivary Gland Epithelial Cells of Sjögren’s Syndrome Patients, Both Constitutively and upon Exposure to Necrotic Cells Debris
Aglaia G Vakrakou^1,2, Markos D Patsouras¹, Panagiotis G Vlachoyiannopoulos¹, Athanasios G Tzioufas¹ and Menelaos N Manoussakis^2,3, ¹Department of Pathophysiology, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece, ²Hellenic Pasteur Institute, Athens, Greece., Hellenic Pasteur Institute, Athens, Greece, Athens, Greece, ³Department of Pathophysiology, School of Medicine, University of Athens, Greece, Department of Pathophysiology, School of Medicine, University of Athens, Greece, Athens, Greece
Background/Purpose: Sjögren’s syndrome (SS) patients manifest inflammation in salivary glands (SG) (lymphocytic infiltration of salivary and lachrymal glands) and evidence of intrinsic activation in the…
Abstract Number: 1034 • 2016 ACR/ARHP Annual Meeting
Microrna-146a Controls Local Bone Destruction By Regulating Fibroblast Induced Osteoclastogenesis in Inflammatory Arthritis
Victoria Saferding¹, Antonia Puchner², Eliana Goncalves-Alves³, Melanie Hofmann³, Julia Brunner⁴, Emine Sahin⁴, Silvia Hayer⁵, Philippe Georgel⁶, Marije M. Koenders⁷, Gernot Schabbauer⁴, Josef S. Smolen⁸, Günter Steiner⁹, Kurt Redlich³ and Stephan Blüml¹⁰, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Vascular Biology and Thrombosis research, Medical University of Vienna, Vienna, Austria, ⁵Waehringer Guertel 18-20 A-A09, Medical University of Vienna, Vienna, Austria, ⁶Centre de Recherche en Immunologie et Hématologie, Université de Strasbourg, Strasbourg, France, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁸Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁰Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: MicroRNA (MiR-) 146a plays an important role in the regulation of the innate immune response and has also been shown to suppress cancer development…
Abstract Number: 1096 • 2016 ACR/ARHP Annual Meeting
Augmentation of Wnt Signaling By IL-1β in Fibroblast-like Synoviocytes
Satoshi Yamasaki¹, Yusuke Yoshida² and Eiji Sugiyama², ¹Hiroshima University Hospital, Hiroshima, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Wnt family proteins canonically stabilize β-catenin to activate T-cell factor (TCF) for the transcription of several genes, including Runx2, which is important for osteoblastogenesis.…
Abstract Number: 1120 • 2016 ACR/ARHP Annual Meeting
Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression
Satoshi Yamasaki, Yusuke Yoshida and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Changes in gene expression are closely related to inflammation and joint destruction in RA. Recently, it has been recognized that post-transcriptional regulation of the…
Abstract Number: 1459 • 2016 ACR/ARHP Annual Meeting
Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra
Anais Levescot¹, Allyn Morris² and Peter Nigrovic³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: IL-1 blockade is highly effective for systemic juvenile idiopathic arthritis (sJIA), but clinical observations raise the possibility that initiation of treatment in a “window…
Abstract Number: 1963 • 2016 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevated in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Free Active TGF-b1 Levels, IL-1b and IL-17A
Markos Patsouras, Athanasios G. Tzioufas and Panayiotis G Vlachoyiannopoulos, School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein secreted by platelets upon…
Abstract Number: 2122 • 2016 ACR/ARHP Annual Meeting
KiSS1 Is a Regulator of ADAMTS4 and ADAMTS5 Expression and Is Post-Transcriptionally Regulated By Micro-RNA N105 in Human OA Chondrocytes
Mohammad Shahidul Makki^1,2 and Tariq Haqqi³, ¹4209 St Rt 44 PO Box 95, Northeast Ohio Medical University, Rootstown, OH, ²Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, ³Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Background/Purpose: Osteoarthritis (OA) is a chronic and debilitating disease of the articulating joints in every population. Micro-RNAs are ~22 nucleotides long non-coding single stranded RNAs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].